Study wrapper · #141
Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis.
Editor's note
A small systematic review and meta-analysis (only 3 eligible studies, n=430) examining semaglutide in non-diabetic patients with obesity and CKD or hypertension, an understudied group. Researchers reported reductions in BMI, better blood-pressure control, and improved renal parameters (eGFR, albuminuria) across the included studies. The direction is consistent with semaglutide's cardiorenal data in diabetes, but the evidence here is thin and heterogeneous by design: three studies of very different types (one RCT, one observational dialysis study, one post hoc analysis), widely varying effect sizes (BMI reductions ranged from 1.5% to 18.3%), and a small total sample. The authors' phrasing that it is "effective and well-tolerated" outruns what three mixed studies can support. Weight this as a preliminary, hypothesis-generating synthesis pointing to a genuine evidence gap, not as a basis for expanded use; adequately powered RCTs in this population are needed.
Plain-language abstract
This review combined a small number of studies to ask how semaglutide affects non-diabetic people who have obesity along with chronic kidney disease or high blood pressure, a group that has not been well studied. After screening 580 studies, only 3 fit the criteria, covering 430 people in total: one randomized trial, one real-world study in dialysis patients, and one re-analysis of an earlier trial. Pooling them, semaglutide was associated with lower BMI, better blood-pressure control (more people reaching under 130 mmHg), and improved kidney-function measures. However, the effects varied widely between studies, for example weight reductions ranged from about 1.5% to 18.3%. With only three quite different studies and a small overall sample, these findings are preliminary. The authors suggest a possible role in this population, but larger, well-designed randomized trials would be needed before drawing firm conclusions.